Microcapsules containing macrolide lactones abamectin, milbemectin, avermectins, milbemycins, emamectins, ivermectins and mectins in general

A technology of macrocyclic lactone and microcapsules, which is applied in the preservation of human or animal bodies, botany equipment and methods, animal husbandry, etc., and can solve the problems of no indication of emulsifiable activity of emulsifiable oil

Inactive Publication Date: 2012-07-04
GAT MICROENCAPSULATION AG
View PDF1 Cites 29 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Referring to the above-mentioned paper of Yang Kai, those skilled in the art will try to use complex coacervate (gelatin and gum arabic) as the best solution, and it still can only obtain the effective encapsulation of 65% of abamectin in microcapsules
On the other hand, according to Yuan Quing-mei's report, the encapsulation rate is still only 83.24%, and there is no suggestion to imitate the activity of emulsifiable cream at high encapsulation rate (eg, over 90% in our invention)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Microcapsules containing macrolide lactones abamectin, milbemectin, avermectins, milbemycins, emamectins, ivermectins and mectins in general
  • Microcapsules containing macrolide lactones abamectin, milbemectin, avermectins, milbemycins, emamectins, ivermectins and mectins in general
  • Microcapsules containing macrolide lactones abamectin, milbemectin, avermectins, milbemycins, emamectins, ivermectins and mectins in general

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 2

[0076] Example 2 - Sustained Release Formulation

[0077] The present invention can take advantage of the UV protective synergistic activity of the formulation ingredients, their chemical compatibility with the mectins, their demonstrated sufficient biological activity and their good physicochemical properties for sustained release formulations of the mectins. This preparation is an embodiment of the present invention in terms of sustained release of macrolides, and the mibaycin (milbemycin A 3 and A 4 ) and Abamectin (Abamectin B 1a and B 1b ) microencapsulation is illustrated.

[0078] Formulation of Example 2.A

[0079]

[0080] The formulations according to the invention meet the stated requirements and show increased UV protection compared to the conventional EC formulations of Abamectin and Mibamectin detailed below (comparative formulations), and of course also compared to prior art formulations Improved particle size uniformity and physical stability of the for...

Embodiment 3

[0084] Example 3 - Encapsulation levels of mectins compared to similar methods of the prior art

[0085] A formulation very similar to the formulation claimed in the invention and method was prepared for comparison according to the method of the invention and using the following formulation.

[0086] Formulation 3.A

[0087]

[0088] Formulation 3.B

[0089] Preparation 3.B of the present invention is the same as Example 1.A, except that abamectin is replaced by ivermectin.

[0090] The encapsulation level of pure ivermectin in formulation 3.A (microencapsulated based on the same reaction as our invention) was only 61%, while that of 3.B was 94.7%. This demonstrates that the degree of microencapsulation of the present invention is superior to that of conventional polyurea / polyurethane microencapsulation. We purposefully chose 3A because it is a close modification of the published microencapsulation method for the insecticide clomazone (which has been shown to control vol...

Embodiment 4

[0091] Example 4 - Mixed formulation of microencapsulated macrolides and suspended neonicotinoids

[0092]As detailed in the description, the present invention provides for any possible combination of active ingredients as long as there is no incompatibility (chemical and / or physicochemical). A representative example is the combination of 15% suspension concentrate of imidacloprid and thiamethoxam (ratio 1:1 wt.-%) and 3% microencapsulated abamectin.

[0093] To carry out this combination, a suspension concentrate of imidacloprid and thiamethoxam with the target concentrations is first prepared by any prior art method. Then prepare the microencapsulated formulation of Abamectin according to embodiment 1.A, wherein the active ingredient is increased accordingly and the same amount of water is reduced. In the microencapsulation preparation of avermectin, add any necessary surfactant in addition to make the microcapsules well dispersed in the suspending agent (for example, 1:1:1...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Microencapsulated formulations of macrolide lactones (abamectin, milbemectin, milbemycins emamectin, avermectins, ivermectins) wherein the active ingredient is protected from UV-degradation, with exceptional release characteristics resembling those of an emulsion concentrate or, if desired, of long-lasting effect; further with appropriate rheological properties, and with reduced toxicity. The invention provides a unique microencapsulation process for the chemical stability and biological activity of mectins, e.g. abamectin, and provides microcapsules of mectins to be used in formulations CS, WG/CS, ZC, EC/CS and any formulation type containing microcapsules and combination with other biologically active ingredients.

Description

technical field [0001] The present invention relates to microbial origin (preferably from Streptomyces avermitilis (Streptomyces avermitilis), Streptomyces spp.), or synthetic or DNA recombinant origin including abamectin, ivermectin, milbemyces Microencapsulation of macrolides including milbemycin (eg milbemicyn oxime), emamectin (eg emamectin benzoate). Background technique [0002] The actinomycete Streptomyces avermitilis produces a series of chemically related compounds characterized by helminticidal, acaricidal, scabicidal and insecticidal properties, the abamectins (trade name: Abamectin, which is abamectin A mixture of B1a and abamectin B1b) is the most representative class. Reports on their structure and specific antiparasitic activity date back to 1975; in particular Mrozik et al. disclose their activity in Tetrahedron Letters (Jan 1983); 24(48) pp.5333-5336). The activity of abamectin and the related compounds ivermectin and milbemycin is currently believed to b...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A01N43/90A01N25/28
CPCA01N43/90A01N25/28A01N2300/00A01N25/30
Inventor V·卡萨纳希尔内M·西梅诺谢拉B·西梅诺谢拉
Owner GAT MICROENCAPSULATION AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap